Table 2.

Results of the disproportionality analysis for PPI-associated CVEs (total and specific).

Drug	N	IC	IC025	IC975	ROR	ROR025	ROR975
PPIs	62,140	−0.37	−0.39	−0.36	0.74	0.74	0.75
Omeprazole	25,713	−0.43	−0.45	−0.41	0.71	0.70	0.72
Lansoprazole	8,846	−0.67	−0.70	−0.63	0.60	0.58	0.61
Pantoprazole	20,653	−0.09	−0.11	−0.06	0.93	0.92	0.95
Rabeprazole	2,250	−0.19	−0.26	−0.12	0.86	0.82	0.90
Ilaprazole	0	−2.89			0.12
Esomeprazole	3,141	−0.14	−0.20	−0.08	0.90	0.86	0.93
Dexlansoprazole	1,537	−1.34	−1.43	−1.26	0.36	0.34	0.38

CVEs, cardiac and vascular events; N, number of records; IC, information components; ROR, reporting odds ratio; IC₀₂₅/IC₉₇₅, the lower/upper limit of 95% confidence interval for the IC; PPI, proton pump inhibitors; ROR₀₂₅/ROR₉₇₅, the lower/upper limit of 95% confidence interval for the ROR.